Robson ME, Im SA, Senkus E, et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). J Clin Oncol 35, 2017 (suppl; abstr LBA4).
Neoadjuvant dostarlimab bij mismatch repair-deficiënte tumoren
jul 2025 | Gynaecologische oncologie, Immuuntherapie, Maag-darm-leveroncologie, Uro-oncologie